Abstracts tagged "Surveys"

Abstract Number: 1237 • ACR Convergence 2024
The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
ADRIANA VANEGAS¹, Guillermo Quiceno², Luis Lira³, Gina Ochoa⁴, Álvaro Arbeláez-Cortés⁵, Mauricio Restrepo-Escobar⁶ and Virginia Pascual Ramos⁷, ¹HOSPITAL SAN VICENTE FUNDACION - UNIVERSIDAD DE ANTIOQUIA - Asociación Colombiana de Reumatología (ASOREUMA), MEDELLIN, Colombia, ²University of Tennessee Graduate School of Medicine, Dallas, TX, ³Sociedad Chilena de Reumatología, Santiago, Chile, ⁴Fundación LICAR, Barranquilla, Colombia, ⁵Clínica IMBANACO, Cali, Colombia, ⁶Universidad de Antioquia, Retiro, Colombia, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico
Background/Purpose: Scientific evidence supports that shared decision-making (SDM) can improve adherence to treatment, patient satisfaction, quality of life, clinical outcomes, and healthcare costs. However, challenges…
Abstract Number: 1739 • ACR Convergence 2024
Adult and Pediatric Rheumatology Fellow Education on Temporomandibular Joint (TMJ) Arthritis in Patients with Juvenile Idiopathic Arthritis
Sarah Bayefsky¹, Meghan Ryan², Nancy Pan³, Tova Ronis⁴, Marinka Twilt⁵, Melissa Lerman⁶ and CARRA TMJ Workgroup⁷, ¹University of Pennsylvania/Children's Hospital of Philadelphia, PHILADELPHIA, PA, ²Unity Point - Blank Children's Hospital, Booneville, IA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Children's National Hospital, Washington, DC, ⁵Alberta Children's Hospital, Calgary, AB, Canada, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷CARRA, Washington, DC
Background/Purpose: Arthritis of the temporomandibular joint, or TMJ arthritis, is an underrecognized manifestation of juvenile idiopathic arthritis (JIA). The absence of prompt treatment may lead…
Abstract Number: 1241 • ACR Convergence 2024
Optimizing Communication of Methotrexate (MTX) Side Effects: A Patient-Centered Approach Focused on Learning Styles and Preferred Language
Veena Patel¹, Sophia Dove² and Veronica Chavez³, ¹Dell Medical School - UT Health Austin, Austin, TX, ²Moody College of Communication, The University of Texas at Austin, Austin, TX, ³University of Texas - Dell Medical School, Austin, TX
Background/Purpose: Methotrexate (MTX) remains the first-line treatment for RA due to its effectiveness and affordability, but communicating its complex regimen and instructions can be challenging,…
Abstract Number: 1740 • ACR Convergence 2024
Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety
Jaime Flores Gouyonnet¹, Mariana Gonzalez-Trevino¹, Cynthia Crowson¹, Ryan Lennon¹, Alain Sanchez-Rodriguez², Gabriel Figueroa-Parra³, Elena Joerns⁴, Bradly Kimbrough⁵, Maria Cuellar-Gutierrez¹, Erika Navarro-Mendoza¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Large language models (LLMs) are increasingly becoming a common source of information for clinicians. We aimed to evaluate the accuracy, quality, and safety of…
Abstract Number: 1244 • ACR Convergence 2024
Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO
Alain Lescoat¹, Yen Chen², Rosemary Gedert², Neda Kortam², Nadia Vann², David Cella³, Sara Shaunfield⁴, Susan Murphy⁵ and Dinesh Khanna², ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³Northwestern University, Chicago, IL, ⁴Northwestern University, Chicago, ⁵University of Michigan, Plymouth, MI
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that…
Abstract Number: 2111 • ACR Convergence 2024
An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis
Lauren King¹, Armaghan Mahmoudian², Jean Liew³, Quike Wang⁴, Ian Stanaitis⁵, Dieuwke Schiphof⁶, Leigh Callahan⁷, David Hunter⁸, Tom Appleton⁹, Aleksandra Turkiewicz¹⁰, Martin Englund¹¹, Stefan Lohmander¹¹, Ida Kristin Haugen¹², Tuhina Neogi¹³, Gillian Hawker¹ and Jos Runhaar⁶, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, ¹University of Toronto, Toronto, ON, Canada, ²University of West Florida, Pensacola, FL, ³Boston University, Boston, MA, ⁴Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), ⁵Women's College Hospital, Toronto, ON, Canada, ⁶Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁷University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ⁸Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁹The University of Western Ontario, London, ON, Canada, ¹⁰,Lund University, Lund, Sweden, ¹¹Lund University, Lund, Sweden, ¹²Diakonhjemmet Hospital, Oslo, Norway, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). The goal is to establish…
Abstract Number: 0157 • ACR Convergence 2024
Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists care for difficult to manage chronic diseases, necessitating adjustments to new treatments and evolving patient views. When making treatment decisions, rheumatologists incorporate clinical…
Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Xenofon Baraliakos¹, Victoria Navarro Compán², Elena Nikiphorou³, Thao Pham⁴, Francesco Ciccia⁵, Megan Hughes⁶, Bruno Kranz⁶, Anna Jus⁷, Chris Watson⁷, Jo Lowe⁸ and Sofia Ramiro⁹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³King's College London, London, United Kingdom, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Alfasigma S.p.A., Bologna, Italy, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
Abstract Number: 2162 • ACR Convergence 2024
Exploring Barriers to Rheumatoid Arthritis Treatment Changes: Insights into Patient Concerns
Nicholas McCormick¹, Jeffrey Curtis², Amy Mudano³, Shilpa Venkatachalam⁴, Kelly Gavigan⁵, Fenglong xie⁶, Patrick Stewart⁷ and Kimberly Garza¹, ¹Auburn University, Auburn, AL, ²Illumination Health, Birmingham, AL, ³Illumination Health, Hoover, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁷Illumination Health, Vero Beach, AL
Background/Purpose: People with rheumatoid arthritis (RA) often hesitate to adjust their treatment due to concerns about medication risks and benefits. This study investigates RA patients'…
Abstract Number: 0164 • ACR Convergence 2024
Sleep Quality Is Associated with Perceived Memory Performance in Females with Osteoarthritis: A Population-based Cross-sectional Study
Linda Li¹, Hui Xie², Leo Lu³, Helen Prlic³, Diane Lacaille⁴, J. Antonio Avina-Zubieta⁴, Jolanda Cibere⁵ and John Esdaile³, and PRECISION Team, ¹Arthritis Research Canada & University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Osteoarthritis (OA) is associated with increased risks of cognitive impairment. Cognitive health is affected by an interplay of lifestyle, metabolic, and biological factors; however,…
Abstract Number: 1252 • ACR Convergence 2024
Rheuminating About Drugs, Sex, and Alcohol? Assessing the Informational Needs of Adolescents and Young Adults with Rheumatic Disease
Matthew Sholdice¹, Meghan Pancucci², gauri gupta³, Simran Heera⁴, KAREN BEATTIE⁵ and Michelle Batthish⁶, ¹McMaster University, London, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Univeresity, Hamilton, Canada, ⁴McMaster University, Mississauga, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Adolescents and young adults (AYA) with chronic rheumatic disease (RD) often engage in behaviours, such as alcohol consumption, recreational drug use, and sexual activity,…
Abstract Number: 2164 • ACR Convergence 2024
Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
Merve Aksoy*, Pamela Gonzalez Manrique, Heinrich-Karl Greenblatt and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI
Background/Purpose: Acute infections are common among rheumatology outpatients receiving immunosuppressive medications (IS). Expert guidance advises pausing IS during acute infection, resuming only when clinically improved,…
Abstract Number: 0203 • ACR Convergence 2024
Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort
Beth Wallace¹, Bryant England², Joshua Baker³, Sauer brian⁴, Jorge Rojas⁵, Punyasha Roul⁶, Michael George⁷, Katherine Wysham⁸, Hannah Brubeck⁹, Isaac Smith¹⁰, Liron Caplan¹¹, Paul Monach¹², Gail Kerr¹³, Gary Kunkel¹⁴, Tawnie Braaten¹⁵, Ted Mikuls² and grant Cannon¹⁶, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶UNMC, Omaha, NE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹VA Puget Sound Health Care System, Seattle, WA, ¹⁰Duke Department of Medicine; VA Durham Healthcare System, Durham, NC, ¹¹Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ¹²VA Boston Healthcare System, Boston, MA, ¹³Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁴University of Utah/VA Salt Lake City Health Care, Salt Lake City, UT, ¹⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ¹⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Administrative claims are often used to evaluate oral glucocorticoid (GC) use in RA for clinical and research purposes, despite limited evidence to support their…
Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 2165 • ACR Convergence 2024
Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
SHAHD FARAJALLAH¹, Katie Dunnock², Qing Yu³, Sangeeta Sule⁴ and Tova Ronis⁴, ¹Children's national hospital, Washington DC, ²George Washington University, washington dc, ³George Washington University, washington dc, DC, ⁴Children's National Hospital, Washington, DC
Background/Purpose: Adolescents and young adults diagnosed with rheumatic diseases often require treatment with teratogenic and cytotoxic medications to effectively manage their conditions. While these therapies…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].